82 related articles for article (PubMed ID: 9829728)
1. Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells.
Ghosh S; Zheng Y; Jun X; Narla RK; Mahajan S; Navara C; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1998 Nov; 4(11):2657-68. PubMed ID: 9829728
[TBL] [Abstract][Full Text] [Related]
2. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells.
Uckun FM; Narla RK; Jun X; Zeren T; Venkatachalam T; Waddick KG; Rostostev A; Myers DE
Clin Cancer Res; 1998 Apr; 4(4):901-12. PubMed ID: 9563884
[TBL] [Abstract][Full Text] [Related]
5. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
[TBL] [Abstract][Full Text] [Related]
6. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of a series of tyrphostins containing nitrothiophene moieties as possible epidermal growth factor receptor tyrosine kinase inhibitors.
Brunton VG; Kelland LR; Lear MJ; Montgomery GJ; Robertson JH; Robins DJ; Queen J; Workman P
Anticancer Drug Des; 1996 Jun; 11(4):265-95. PubMed ID: 8679052
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antiproliferative activity of unsaturated quinoline derivatives.
Montgomery GJ; McKeown P; McGown AT; Robins DJ
Anticancer Drug Des; 2000 Jun; 15(3):171-81. PubMed ID: 11049085
[TBL] [Abstract][Full Text] [Related]
9. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects.
Antonello A; Tarozzi A; Morroni F; Cavalli A; Rosini M; Hrelia P; Bolognesi ML; Melchiorre C
J Med Chem; 2006 Nov; 49(23):6642-5. PubMed ID: 17154492
[TBL] [Abstract][Full Text] [Related]
10. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antiproliferative activity of tyrphostins containing quinoline moieties.
Brunton VG; Lear MJ; McKeown P; Robins DJ; Workman P
Anticancer Drug Des; 1996 Sep; 11(6):463-83. PubMed ID: 8836111
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.
Abouzid K; Shouman S
Bioorg Med Chem; 2008 Aug; 16(16):7543-51. PubMed ID: 18678492
[TBL] [Abstract][Full Text] [Related]
16. Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
Harper ME; Goddard L; Glynne-Jones E; Assender J; Dutkowski CM; Barrow D; Dewhurst OL; Wakeling AE; Nicholson RI
Prostate; 2002 Jun; 52(1):59-68. PubMed ID: 11992620
[TBL] [Abstract][Full Text] [Related]
17. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of a series of hydroxybenzylphenylamine derivatives as inhibitors of EGF receptor-associated tyrosine kinase activity.
Chen H; Bashiardes G; Mailliet P; Commercon A; Sounigo F; Boiziau J; Parker F; Tocque B; Roques BP; Garbay C
Anticancer Drug Des; 1996 Jan; 11(1):49-71. PubMed ID: 8639248
[TBL] [Abstract][Full Text] [Related]
19. Bombesin and epidermal growth factor potentiate the effect of cytotoxic LH-RH analog AN-152 in vitro.
Krebs LJ; Wang X; Nagy A; Schally AV; Prasad PN; Liebow C
Int J Oncol; 2002 Dec; 21(6):1325-9. PubMed ID: 12429984
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
Bridges AJ; Zhou H; Cody DR; Rewcastle GW; McMichael A; Showalter HD; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1996 Jan; 39(1):267-76. PubMed ID: 8568816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
